Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “layout of the company's products on the immunohistochemistry platform,” the company replied that the company's immunohistochemical products focus on CDx (such as c-Met, HER2, Claudin18.2, etc.), which also cover routine immunohistochemical targets for common tumors, and have automated dyeing machines and self-produced secondary reagents and supporting reagents. PD-L1 products have completed pre-testing and admission work in more than 100 hospitals, laying a good foundation for the company to develop the immunohistochemistry market.
艾德生物(300685.SZ)：PD-L1产品已完成100余家医院的预实验及准入工作
Ed Biotech (300685.SZ): PD-L1 products have completed pre-testing and admission work in more than 100 hospitals
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.